ALKS

MKT CAP:$6B

Alkermes plc

Market Cap

$6B

Healthcare·Biotechnology·🇮🇪 Ireland·NASDAQ

Healthcare·Biotechnology·🇮🇪·NASDAQ

Stock Price

$34.03+$5.77 (+20.42%)

Apr 23, 2026

Company Details

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its mark...

CEO

Richard F. Pops

IPO Date

Jul 16, 1991

Website

www.alkermes.com

Key Metrics TTM

Revenue

$1.5B

-4.1% YoY

Net Income

$242M

EPS (Diluted)

$1.43

Free Cash Flow

$480M

Revenue / Share

$8.75

Gross Margin

86.3%

Operating Margin

17.2%

Net Margin

16.4%

FCF Margin

32.5%

P/S

3.8x

P/E

23.1x

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Feb 25, 2026

$1.5B-5.2%EPS $1.43

Q4 2025

Feb 25, 2026

$385M-10.6%EPS $0.29

Q3 2025

Oct 28, 2025

$394M+4.2%EPS $0.49

Q2 2025

Jul 29, 2025

$391MEPS $0.52

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$304M	$251M	$4M
Q3 21	$294M	$245M	-$20M
Q4 21	$324M	$271M	$2M
Q1 22	$279M	$223M	-$27M
Q2 22	$276M	$218M	-$34M
Q3 22	$252M	$202M	-$61M
Q1 23	$288M	$229M	-$11M
Q2 23	$617M	$554M	$281M
Q3 23	$381M	$319M	$89M
Q1 24	$350M	$292M	$43M
Q3 24	$378M	$315M	$105M
Q4 24	$430M	$368M	$163M
Q1 25	$307M	$257M	$14M
Q2 25	$391M	$341M	$93M
Q3 25	$394M	$343M	$89M
Q4 25	$385M	$333M	$58M

Valuation

Quarter	P/S	P/E
Q2 21	3.6x	—
Q3 21	4.6x	—
Q4 21	3.3x	—
Q1 22	3.7x	—
Q2 22	4.2x	—
Q3 22	3.3x	—
Q1 23	4.4x	—
Q2 23	3.5x	50.2x
Q3 23	3.0x	26.2x
Q1 24	2.8x	16.4x
Q3 24	2.7x	11.2x
Q4 24	3.1x	14.7x
Q1 25	3.7x	18.3x
Q2 25	3.1x	13.4x
Q3 25	3.1x	14.1x
Q4 25	3.1x	19.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	$33M	$27M
Q3 21	$83M	$78M
Q4 21	$31M	$22M
Q1 22	$22M	$14M
Q2 22	-$2M	-$12M
Q3 22	$625.0K	-$10M
Q1 23	-$21M	-$28M
Q2 23	$216M	$206M
Q3 23	$100M	$85M
Q1 24	$21M	$13M
Q3 24	$82M	$73M
Q4 24	$190M	$181M
Q1 25	$99M	$89M
Q2 25	$150M	$137M
Q3 25	$102M	$84M
Q4 25	$170M	$170M

Capital Expenditures

Quarter	CapEx
Q2 21	$7M
Q3 21	$5M
Q4 21	$9M
Q1 22	$8M
Q2 22	$10M
Q3 22	$10M
Q1 23	$7M
Q2 23	$10M
Q3 23	$14M
Q1 24	$8M
Q3 24	$8M
Q4 24	$10M
Q1 25	$10M
Q2 25	$13M
Q3 25	$17M
Q4 25	$20.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 21	+22.7%	+6.4%
Q3 21	+11.0%	+13.8%
Q4 21	+15.9%	+3.7%
Q1 22	+10.8%	+13.9%
Q2 22	-9.1%	+3.8%
Q3 22	-14.2%	-0.3%
Q1 23	-11.4%	-7.3%
Q2 23	+121.7%	+10.2%
Q3 23	+37.9%	-6.1%
Q1 24	+38.8%	-1.9%
Q3 24	+31.5%	-8.4%
Q4 24	-30.4%	-20.5%
Q1 25	-19.5%	+0.3%
Q2 25	+11.5%	-3.1%
Q3 25	+4.2%	+11.6%
Q4 25	-10.6%	+22.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$28M	9.1%
Q3 21	$26M	8.7%
Q4 21	$19M	5.9%
Q1 22	$0	0.0%
Q2 22	$0	0.0%
Q3 22	$26M	10.3%
Q1 23	$21M	7.3%
Q2 23	$29M	4.6%
Q3 23	$24M	6.3%
Q1 24	$33M	9.3%
Q3 24	$23M	6.0%
Q4 24	$21M	4.8%
Q1 25	$23M	7.4%
Q2 25	$25M	6.4%
Q3 25	$25M	6.3%
Q4 25	-$72M	-18.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 21	$97M	$53M	$86M	—
Q3 21	$118M	$48M	$88M	—
Q4 21	$98M	—	—	$160M
Q1 22	$96M	$49M	$96M	—
Q2 22	$93M	$55M	$95M	—
Q3 22	$100M	$56M	$97M	—
Q1 23	$64M	$49M	$119M	—
Q2 23	$68M	$58M	$138M	—
Q3 23	$65M	$42M	$115M	—
Q1 24	$68M	$54M	$126M	—
Q3 24	$60M	$48M	$102M	—
Q4 24	$57M	$48M	$99M	—
Q1 25	$72M	$49M	$123M	—
Q2 25	$77M	$50M	$121M	—
Q3 25	$82M	—	—	$172M
Q4 25	$93M	—	—	$187M

Revenue Segments

Quarter	Manufactured Product And Royalty	Product
Q1 25	$62M	$244M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$283M	$246M	$529M
Q2 22	$255M	$326M	$581M
Q3 22	$264M	$316M	$580M
Q4 22	$292M	$316M	$608M
Q1 23	$321M	$279M	$600M
Q2 23	$666M	$163M	$829M
Q3 23	$648M	$241M	$889M
Q4 23	$457M	$316M	$773M
Q1 24	$421M	$324M	$745M
Q2 24	$535M	$341M	$876M
Q3 24	$396M	$513M	$909M
Q4 24	$291M	$461M	$752M
Q1 25	$400M	$484M	$884M
Q2 25	$521M	$495M	$1.0B
Q3 25	$616M	$495M	$1.1B
Q4 25	$1.1B	$200M	$1.3B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	164M	+2.7%	+3.2%
Q3 21	161M	-1.5%	+1.5%
Q4 21	162M	+0.2%	+1.7%
Q1 22	162M	+0.4%	+1.8%
Q2 22	164M	+0.8%	-0.1%
Q3 22	164M	+0.3%	+1.8%
Q1 23	165M	+0.5%	+2.0%
Q2 23	172M	+3.9%	+5.6%
Q3 23	172M	+0.2%	+4.9%
Q1 24	173M	+0.6%	+5.3%
Q3 24	167M	-3.4%	+1.2%
Q4 24	167M	-0.3%	-2.9%
Q1 25	169M	+1.3%	-1.8%
Q2 25	168M	-0.2%	-2.7%
Q3 25	169M	+0.1%	+0.9%
Q4 25	169M	+0.1%	+1.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	$135.3K	2K
Q3 21	$131.0K	2K
Q4 21	$146.7K	2K
Q1 22	$126.0K	2K
Q2 22	$124.9K	2K
Q3 22	$114.1K	2K
Q1 23	$126.1K	2K
Q2 23	$270.8K	2K
Q3 23	$167.1K	2K
Q1 24	$166.8K	2K
Q3 24	$180.1K	2K
Q4 24	$238.9K	2K
Q1 25	$170.3K	2K
Q2 25	$217.0K	2K
Q3 25	$219.0K	2K
Q4 25	$187.6K	2K

Revenue / Employee